New drug duo shows promise in tough lung cancer

NCT ID NCT02523469

Completed Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a combination of two drugs—nivolumab (Opdivo) and ALT-803—in 67 people with advanced non-small cell lung cancer that had not responded to prior treatments. The goal was to find a safe dose and see if the combination could shrink tumors. The trial is now complete, and results will help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo) and ALT-803 (an immune-boosting protein)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced lung cancer who have not responded to other therapies.
What could go wrong: This is an early-phase trial with only 67 participants, so results may not apply to everyone. The combination may cause significant side effects or fail to improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Cleveland Clinic Florida

Weston, Florida, 33331, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.